Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143532 · ClinicalTrials.gov registry record
Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 26
- Enrollment target
NCT01143532: Completed study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT01143532 is a clinical trial that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01143532 has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
Background: \- Genetic variation in a particular chromosome is a major contributor to the increased risk for kidney disease that is common in people of African descent, although the specific gene, mutations, and other aspects of the variations remain to be determined. By studying the outcomes of kidney transplant in donors and recipients of African descent, researchers hope to better understand the effects of this genetic variation on the success of kidney transplants. Objectives: \- To examine possible connections between genetic variations and kidney transplant outcomes for donors and recipients. Eligibility: * Participants in kidney transplant where both donor and recipient were of black African descent. * Eligible transplants include both living donor and deceased donor. Design: * The study will involve one visit of up to 8 hours. * All participants will provide a detailed personal and family medical history. * All participants will provide blood and urine samples, including a 24-hour urine collection, to test kidney function and collect material for genetic testing. * Donor participants will also have a magnetic resonance imaging (MRI) scan of their remaining kidney.
Primary Outcome
Will identify 300 kidney transplant dyads (donor/recipient pairs), which both individuals were of African descent and the kidney transplants were performed between 1995-2006. We hypothesize that genetic variants in the kidney donor affect kidney donor outcomes. Kidney donors have an increased prevalence of microalbuminuria.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-08-12 |
| Est. Completion | 2015-10-19 |
What the finished NCT01143532 record still lists
NCT01143532 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01143532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01143532 about?
NCT01143532 is a clinical study titled "Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes". Background: \- Genetic variation in a particular chromosome is a major contributor to the increased risk for kidney disease that is common in people of African descent, although the specific gene, mutations, and other aspects of the variations remain to be determined. By studying the outcomes of ki...
What is the current status of trial NCT01143532?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2010-08-12. Estimated completion is 2015-10-19.
Who is sponsoring clinical trial NCT01143532?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI